| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Significant intimal hyperplasia was formed with loss of functions of both endothelium-derived nitric oxide (EDNO) and endothelium-derived hyperpolarizing factor (EDHF) in rabbit autologous jugular vein graft under poor distal runoff. Ezetimibe (a selective cholesterol transport inhibitor) and vildagliptin (a dipeptidyl peptidase-4 inhibitor) each in part recovered the function of EDNO (but not EDHF) and reduced intimal hyperplasia. In contrast, in rabbit autogenous carotid artery graft model, receptor-mediated, endothelium-dependent relaxation was enhanced by increased function of EDNO (but not of EDHF). The intimal thickening was minimal, suggesting that better patency of autogenous arterial graft is considered when compared with that of vein graft in aortocoronary revascularization. These results suggest that upregulation of the EDNO function could be beneficial in reducing intimal hyperplasia in both artery graft and vein graft.
|
